SCHEMBL2698920

SCHEMBL2698920

O=[C]CNO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2428440 0.67
SCHEMBL208575 0.64
SCHEMBL6251728 0.62
SCHEMBL293653 0.62
SCHEMBL4835428 0.61
SCHEMBL3895041 0.61
SCHEMBL9407380 0.61
SCHEMBL10840976 0.61
SCHEMBL137444 0.59
SCHEMBL10425783 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111432815-A Enhancing cancer treatment efficacy via sphingosine-1-phosphate pathway AC生物科学公司 2020-07-17 CN claimed
EP-0126344-A2 Tripeptide esters of therapeutic agents ABBOTT LABORATORIES (US) 1984-11-28 EP claimed
US-20210395189-A1 SUBSTITUTED TETRACYCLINE COMPOUNDS PARATEK PHARMACEUTICALS, INC. 2021-12-23 US disclosed
EP-3812372-A2 7-HETEROCYCLYL SUBSTITUTED SANCYCLINE DERIVATIVES FOR TREATING BACTERIAL, VIRAL AND PARASITIC INFECTIONS (E.G. MALARIA) OR INFLAMMATORY DISEASES Paratek Pharmaceuticals, Inc. (US) 2021-04-28 EP disclosed
CN-111432815-A Enhancing cancer treatment efficacy via sphingosine-1-phosphate pathway AC生物科学公司 2020-07-17 CN disclosed
EP-3045449-A1 TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS Paratek Pharmaceuticals, Inc. (US) 2016-07-20 EP disclosed
US-20160046561-A1 SUBSTITUTED TETRACYCLINE COMPOUNDS PARATEK PHARMACEUTICALS, INC. 2016-02-18 US disclosed
US-9012433-B2 Substituted tetracycline compounds PARATEK PHARMACEUTICALS, INC. (US) 2015-04-21 US disclosed
US-20130102779-A1 Substituted Tetracycline Compounds PARATEK PHARMACEUTICALS, INC. (US) 2013-04-25 US disclosed
US-8318706-B2 Substituted tetracycline compounds PARATEK PHARMACEUTICALS, INC. (US) 2012-11-27 US disclosed
EP-2455367-A1 Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections Paratek Pharmaceuticals, Inc. (US) 2012-05-23 EP disclosed
EP-0863878-B1 CYCLIC NITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AVENTIS PHARMA INC (US) 2003-01-08 EP disclosed
EP-1255727-A1 ACETAL HYDROXYLAMINE COMPOUNDS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2002-11-13 EP disclosed
WO-2001060785-A1 ACETAL HYDROXYLAMINE COMPOUNDS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2001-08-23 WO disclosed
US-5962469-A PREVENTION OF OXIDATION TISSUE DAMAGE BY FREE RADICALS HOECHST MARION ROUSSEL INC. (US) 1999-10-05 US disclosed
EP-0863878-A1 CYCLIC NITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM HOECHST MARION ROUSSEL, INC. (US) 1998-09-16 EP disclosed
WO-1997010218-A1 CYCLIC NITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM HOECHST MARION ROUSSEL, INC. (US) 1997-03-20 WO disclosed
EP-0280610-B1 DIPEPTIDES, PREPARATION PROCESS AND USE IN DOSING PROTEASES SERBIO (FR) 1992-10-21 EP disclosed
EP-0252482-A2 7-Acyloxy-6-aminoacyloxypolyoxylabdanes, process for their preparation and their use as medicine HOECHST AKTIENGESELLSCHAFT (DE) 1988-01-13 EP disclosed
EP-0217372-A2 Polyoxygenated labdane derivatives, process for their preparation and their use as medicaments HOECHST AKTIENGESELLSCHAFT (DE) 1987-04-08 EP disclosed